Clinical Trial Update: Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating BV in combination with tislelizumab for CD30+ relapsed/refractory NK/T-cell lymphoma, focusing on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nk T-cell Lymphoma

Drugs mentioned

• BV
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: NK/T Cell Lymphoma Nos | Phase 2 | Status: UNKNOWN